Trial Profile

A phase III trial of CA-002 for the treatment of peanut allergies: A randomized, double-blind, placebo-controlled study

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CA 002 (Primary)
Indications Peanut hypersensitivity
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Camallergy

Most Recent Events

08 Jan 2021 According to a Camallergy media release, company is planning IND (Investigational New Drug) and IMPD (Investigational Medicinal Product Dossier) applications in the US, UK, and EU to initiate our pivotal Phase 3 studies to commence this year upon the closing of our Series B round
06 Nov 2019 According to a Camallergy media release, the company plans to initiate a randomized, double-blind, placebo-controlled Phase 3 clinical trial by mid-year 2020.
26 Oct 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com